Pharmacogenetics: The ethical context

Pharmacogenomics Journal

Volumn 1, Issue 4, 2001, Pages 239-242

  Thomas, S M ^a  

^a UK Human Genetics Commission   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOETHICS; GENETIC SCREENING; HUMAN; LEGAL ASPECT; METHODOLOGY; PHARMACOGENETICS; REVIEW; UNITED KINGDOM;

BIOETHICAL ISSUES; GENETIC SCREENING; GREAT BRITAIN; HUMANS; PHARMACOGENETICS;

EID: 0035750320     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500052     Document Type: Article

References (5)

1. Roses A. Pharmocogenetics and the practice of medicine. Nature 2000; 405: 857-865.
2. Nuffield Council on Bioethics. Mental Disorders and Genetics: the Ethical Context. Nuffield Council on Bioethics, London, UK, 1998.
3. Drysdale CM et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Not Acad Sei 2000; 97: 10483-10488.
4. Fullerton SM et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origins and maintenance of a major human polymorphism. Am 1 Hum Genet 2000; 67: 881-900.
5. Liggett SB. Pharmacogenetic applications of the Human Genome Project. Nature Med 2001; 7:281-283.